Renaissance Technologies
MDNA

Renaissance Technologies’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Renaissance Technologies’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-85,113
Closed -$25K – 4281
2023
Q3 		$25K Sell
85,113
-5,287
-6% -$2.06K ﹤0.01% 3505
2023
Q2 		$44K Sell
90,400
-59,900
-40% -$37K ﹤0.01% 3640
2023
Q1 		$95K Sell
150,300
-26,242
-15% -$16.3K ﹤0.01% 3506
2022
Q4 		$81K Buy
176,542
+131,142
+289% +$80.1K ﹤0.01% 3687
2022
Q3 		$38K Buy
45,400
+13,300
+41% +$15K ﹤0.01% 3823
2022
Q2 		$37K Sell
32,100
-7,600
-19% -$8.12K ﹤0.01% 4048
2022
Q1 		$51K Sell
39,700
-59,300
-60% -$92.1K ﹤0.01% 3914
2021
Q4 		$161K Buy
99,000
+87,100
+732% +$181K ﹤0.01% 3589
2021
Q3 		$33K Sell
11,900
-20,546
-63% -$50.9K ﹤0.01% 3395
2021
Q2 		$98K Sell
32,446
-108,754
-77% -$402K ﹤0.01% 3360
2021
Q1 		$574K Buy
141,200
+10,700
+8% +$43.6K ﹤0.01% 2857
2020
Q4 		$608K Sell
130,500
-99,400
-43% -$401K ﹤0.01% 2735
2020
Q3 		$945K Buy
+229,900
New +$925K ﹤0.01% 2550

Other funds holding MDNA

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
NDSI
Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Renaissance Technologies's MDNA Position: Q4 2023 in Review

Renaissance Technologies sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q4 2023, closing a stake of 85,113 shares — an estimated $25K sold.

Renaissance Technologies first reported a position in MDNA in Q3 2020 and held it in 13 quarters. The position peaked at $945K in Q3 2020. 3 funds tracked by Wall St. Rank hold MDNA as of Q4 2023.

  • Renaissance Technologies reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q4 2023 after selling out during the quarter.
  • Renaissance Technologies sold 85,113 Medicenna Therapeutics Corp. Common Shares shares in Q4 2023, an estimated $25K.
  • Renaissance Technologies first reported a position in Medicenna Therapeutics Corp. Common Shares in Q3 2020 and held it in 13 quarters.
  • Renaissance Technologies's Medicenna Therapeutics Corp. Common Shares position peaked at $945K in Q3 2020.
  • 3 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q4 2023.

Based on Renaissance Technologies's 13F filing for Q4 2023, filed 13 Feb 2024.